Abstract
1. To assess the general tolerability of axitinib use in advanced renal cell carcinoma in a real-world setting. 2. To audit our axitinib dose modification practice. Using our electronic patient records and prescribing systems, 43 patients with advanced renal cell carcinoma, who had received
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the Royal College of Physicians of London
Paper Title
Journal
Date
